Abbott Announces CE Mark for World's Longest Coronary Drug Elu...

(Comtex SmarTrend(R)) Below are the three companies in the Pharmaceuticals industry with the lowest price to earnings (P/E) ratios. P/E is an important valuation tool when comparing companies in the same industry. A higher P/E ratio means that ...

(Financial News Network On) Below are the top five companies in the Pharmaceuticals industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the potential to ...

Investors in Abbott Laboratories ( NYSE: ABT ) saw new options begin trading today, for the July expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the ABT options chain for the new July contracts and identified one ...

(SmarTrend(R) Upgrades/Downgrades via COMTEX) -- Abbott Laboratories (NYSE:ABT) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $36.59 on volume of 7.1 million shares, above average daily volume of 6.6 million.

Goldman Sachs upgraded Abbott Labs (NYSE: ABT) from Neutral to Buy with a price target of $44.00 (from $38.00). Analyst David H. Roman views Abbott as a fast growing large-cap company with margin expansion potential. "We had been hesitant about the ...

Abbott Laboratories (ABT) Accenture (ACN) Brinker (EAT) Equifax (EFX) General Dynamics (GD) CarMax (KMX) Michael Kors (KORS) Lowe's (LOW)

(FIND, Inc. via COMTEX) -- SUMMARY: EPA will authorize its contractor ABT Associates, Incorporated (ABT) and six (6) auditing organizations: Perry Johnson Registrars, Inc.; SGS North America, Inc.; SAI Global; Orion Registrar, Inc.; NSF-ISR ...

, 06:19 by: SA Editor Miriam Metzinger | includes: ABBV, ABT, ANF, AZO, BAX, BBY, BSX, COV, CPB, CRM, DELL, FL, GNW, HD, HPQ, JNJ, JWN, KO, LOW, NTAP, QCOR, RDN, ROST, SHLD, TGT, TJX, TOL, WFC, WLH, WMT, WSM Stocks discussed on the in-depth ...

Enrollment in Phase 1 Clinical Trials of ABT-199 in Chronic Lymphocytic Leukemia Continues North Chicago, IL /PRNewswire/ - AbbVie (NYSE: ABBV) today announced that data evaluating several investigational compounds in the company's oncology pipeline ...